Independent
Tenure on this board
2.5 yrs
3 nominees · 3 ballot items.
Election of three Class I directors; non-binding, advisory approval of named executive officer compensation (say-on-pay); and ratification of Ernst & Young LLP as independent registered public accounting firm.
Elect three Class I directors — Michael Singer, M.D., Ph.D., Timothy A. Springer, Ph.D., and Patrick Zenner, M.B.A. — to serve until the 2029 Annual Meeting.
Advisory vote to approve, on a non-binding basis, the compensation of the company's named executive officers as disclosed in the proxy statement.
This proposal asks shareholders to cast a non-binding, advisory vote endorsing the overall compensation program for the named executive officers as described in the proxy statement. Management frames the program as designed to attract, retain, and motivate executive talent necessary to advance the company’s late-stage cell therapy pipeline, and notes that compensation emphasizes variable, performance-linked pay (notably significant equity awards) to align executives with long-term shareholder value. The Compensation Committee used competitive peer data and an independent consultant (Compensia) to set pay, and the company highlights features intended to mitigate risk, including a clawback policy, double-trigger change-in-control protections, and limits on hedging/pledging. Contextual factors include the company’s clinical progress in 2025 (FDA SPA agreement, Phase 3 enrollment) and recent corporate transactions (the 2023 merger and subsequent equity-plan treatments), which influenced retention-focused awards and vesting arrangements. The advisory vote is explicitly non-binding, but the Board commits to considering the result when making future pay decisions; management therefore seeks shareholder endorsement to validate its compensation philosophy and practices. Possible governance considerations for an analyst include the high proportion of equity-based compensation (particularly for the CEO), recent special vesting and separation arrangements for certain former executives, and large shareholders with concentrated ownership positions that may influence outcomes or proxy dynamics. Approving the proposal signals shareholder acceptance of the pay framework and retention strategy; a negative vote would likely trigger a shareholder engagement and potential adjustments to compensation design. Given the Board’s unanimous recommendation and the company’s stated reliance on market benchmarking and risk-mitigation measures, management positions this proposal as consistent with promoting long-term value creation while balancing near-term retention needs.
Ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Squarepoint Ops LLC | 7.6% | 2,238,486 | $14M |
| 2 | FMR LLC | 2.2% | 651,649 | $4M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.4% | 407,597 | $3M |
| 4 | BlackRock, Inc. | 1.3% | 373,122 | $2M |
| 5 | 683 Capital Management, LLC | 1.1% | 330,000 | $2M |
| 6 | MILLENNIUM MANAGEMENT LLC | 1.0% | 284,317 | $2M |
| 7 | MARSHALL WACE, LLP | 0.8% | 239,412 | $1M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.8% | 226,500 | $1M |
| 9 | Erste Asset Management GmbH | 0.8% | 221,705 | $1M |
| 10 | STATE STREET CORP | 0.7% | 200,337 | $1M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.